Mineralys Therapeutics Files 8-K

Ticker: MLYS · Form: 8-K · Filed: Mar 10, 2025 · CIK: 1933414

Sentiment: neutral

Topics: 8-K, disclosure, regulatory

TL;DR

Mineralys Therapeutics filed an 8-K on 3/10/25 covering disclosures and other events.

AI Summary

Mineralys Therapeutics, Inc. filed an 8-K on March 10, 2025, to report on various events. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company is incorporated in Delaware and its principal executive offices are located in Radnor, Pennsylvania.

Why It Matters

This 8-K filing provides updates on company events and disclosures, which are important for investors to stay informed about the latest developments at Mineralys Therapeutics.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain any immediately concerning or high-impact information.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Mineralys Therapeutics?

The primary purpose is to report on events that are material to shareholders, including Regulation FD Disclosures, Other Events, and Financial Statements and Exhibits, as of March 10, 2025.

When was Mineralys Therapeutics, Inc. incorporated?

Mineralys Therapeutics, Inc. was incorporated in Delaware.

What is the business address of Mineralys Therapeutics, Inc.?

The business address is 150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania 19087.

What is the SEC file number for Mineralys Therapeutics, Inc.?

The SEC file number for Mineralys Therapeutics, Inc. is 001-41614.

What is the SIC code for Mineralys Therapeutics, Inc.?

The Standard Industrial Classification (SIC) code for Mineralys Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 10, 2025 regarding Mineralys Therapeutics, Inc. (MLYS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing